NBI-1065845
DrugOral tablet
NCT Number: NCT07196501
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 3
Neurocrine Clinical Site, Carlton, Victoria, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Oral tablet
Oral tablet
Time frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)
Contact information is provided by the study sponsor or research team.
Neurocrine Biosciences
Industry
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04061148
Behavior, Behavioral Symptoms
San Francisco, California, United States
View Trial DetailsNCT05538910
Chemically-Induced Disorders, Depressive Disorder
Baltimore, Maryland, United States
View Trial DetailsNCT03973268
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT03065335
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial Details